FDA Grants Priority Review to Palvella Rapamycin Gel

The FDA has set a February 28, 2027 target date for its decision on Palvella Therapeutics' topical QTORIN 3.9% rapamycin gel for a rare vascular condition.

Updated on Nov. 3, 2026 in Biotech

Bold flat-color editorial illustration of an amber gel tube beside a petri dish on a cream surface, in a deep red and cream palette. — Palvella Therapeutics received FDA priority review for its topical QTORIN 3.9% rapamycin gel, with a regulatory decision targeted for February 28, 2027. AI Illustration. Upload story photo >

Palvella Therapeutics, a Nasdaq-listed biotechnology company based in Wayne, Pennsylvania, received priority review from the FDA for its new drug application for QTORIN 3.9% rapamycin anhydrous gel. The agency set a February 28, 2027 target date for its regulatory decision.

Why it matters

The application is supported primarily by the Phase 3 SELVA trial, which met all six prespecified efficacy endpoints with statistical significance. If approved, the topical treatment would become the first FDA-approved therapy for microcystic lymphatic malformations.

The SELVA trial met all six prespecified efficacy endpoints with p-values below 0.001, and 95% of participants aged 6 and older improved on the primary endpoint. Systemic rapamycin levels remained below 2 nanograms per milliliter, though the FDA decision remains pending until February 28, 2027.

The players

Palvella Therapeutics

A Nasdaq-listed biotechnology company based in Wayne, Pennsylvania, developing QTORIN rapamycin for rare vascular and lymphatic malformations.

U.S. Food and Drug Administration (FDA)

The federal agency responsible for reviewing and approving new drug applications in the United States, which granted priority review to the QTORIN application.

The details

QTORIN rapamycin is a topical formulation designed to deliver treatment directly to affected skin, and no drug-related serious adverse events were reported in the trial. The application also includes additional Phase 2 clinical results and published research on off-label rapamycin use.

February 28, 2027: FDA target date for its regulatory decision on QTORIN rapamycin.
First half of 2027: Planned standalone U.S. commercial launch, contingent on regulatory approval.

Regulatory Pathway

QTORIN rapamycin has received Breakthrough Therapy, Fast Track, and Orphan Drug designations from the FDA, a combination that signals the agency's prioritization of rare-disease therapies with limited existing options. The priority review now moves that designation history toward a formal decision on the drug's approval.

If approved, QTORIN rapamycin would offer a topical treatment option for microcystic lymphatic malformations, a condition for which no FDA-approved therapy currently exists. The treatment is applied directly to affected skin rather than delivered systemically.

The takeaway

A topical therapy for a rare vascular condition could offer patients an alternative to systemic treatments if the FDA grants approval by its February 28, 2027 target date. Readers tracking rare-disease drug development can watch that date for the agency's decision.

What happens next

The FDA's regulatory decision on QTORIN 3.9% rapamycin anhydrous gel is targeted for February 28, 2027, and Palvella plans a standalone U.S. commercial launch in the first half of 2027 if approved.